Travere Therapeutics TVTX

Reference table

1. What it is

Travere Therapeutics (Nasdaq: TVTX) is a San Diego-based rare-disease biopharmaceutical company (formerly Retrophin, renamed in November 2020). Founded 2008, IPO 2012, 385 full-time employees, CEO Eric Dube. The company's center of gravity today is a single franchise:

• FILSPARI (sparsentan) — a once-daily, non-immunosuppressive dual endothelin/angiotensin receptor antagonist. It is approved and commercial in IgA nephropathy (IgAN) and is now launching in focal segmental glomerulosclerosis (FSGS), where management says it is the first and only FDA-approved medicine. This is the growth engine.
• Legacy rare-disease products — historically Chenodal, Cholbam (bile-acid disorders) and Thiola/Thiola EC (cystinuria). Note the reported segment history shows the business restructured hard around 2022–23 (bile-acid/tiopronin product lines fall out of the recent segment splits; FY25 reports simply Product $410.5M and License $80.3M), consistent with a portfolio pruning to refocus on FILSPARI.
• Pipeline — pegtibatinase (an enzyme therapy for classical homocystinuria/HCU; Phase 3 HARMONY restarted, topline anticipated 2H 2027) and earlier-stage rare-disease programs, plus a NIH/NCATS collaboration.

Revenue mix (FY25, from the segment file): Product $410.5M (84%) · License $80.3M (16%). The license line is milestone/royalty-driven and lumpy quarter to quarter (see §5) — a genuine caveat when reading any single quarter's "growth."

Geography: the data file's geographic-segment array is empty — so we cannot break out revenue by region from this dataset. Honestly flagged; do not infer a geographic mix. (The one geographic data point available is qualitative: partner Chugai plans a sparsentan NDA in Japan in 2026, a royalty/milestone opportunity rather than TVTX-booked revenue.)

2. The expert thesis — why the (management-only) claims are bullish (traceable)

There is no independent expert-panel coverage of TVTX in the Synthos KB. This is a screen-surfaced name; the honest house standard applies — this note is fundamentals-driven. The KB holds 6 traceable claims, and all 6 are TVTX management (skill weight 0.5 — they talk their own book), sourced from the 2026-05-04 (Q1 FY26) earnings release. We report them for what they are, half-weighted, and build the bear case (§3) from the fundamentals and quant rather than from a countervailing expert:

• FSGS approval is the TAM expander. Management frames the FSGS label as taking FILSPARI's U.S. addressable population to >100,000 patients, supporting "substantial, durable growth" (TVTX-earnings-2026Q2:7d7d03c2e1, conviction 78), and separately notes FILSPARI is the first/only FDA-approved FSGS medicine, targeting >30,000 U.S. patients without nephrotic syndrome, with launch "underway and first reimbursed treatments in week one" (TVTX-earnings-2026Q2:3664165c20, conviction 72).
• IgAN demand is still growing. Management expects "continued FILSPARI IgAN growth from record demand and its foundational position among new and repeat prescribers" (TVTX-earnings-2026Q2:080e6a1ed2, conviction 70).
• Pipeline & partnership optionality. The SPARX study (FILSPARI in post-transplant recurrent IgAN/FSGS) was said to be on track to complete enrollment in Q2 2026 (TVTX-earnings-2026Q2:3a7f40412d, conviction 60); partner Chugai expects to submit a sparsentan NDA in Japan in 2026 with milestone/royalty eligibility (TVTX-earnings-2026Q2:6f9a2efc88, conviction 58); and pegtibatinase's Phase 3 HARMONY restarted dosing with topline data anticipated 2H 2027 (TVTX-earnings-2026Q2:c51d09d0e7, conviction 62).

Honest weighting. Every one of these is the company describing its own launch — useful for the shape of the opportunity (which diseases, roughly how many patients, what's next), useless as independent valuation support. Treat the ">100,000 patient" TAM as an addressable-population figure, not a revenue forecast; penetration, pricing, persistence and competition (§8) determine what actually converts to sales. There is no independent bull and no independent bear in the KB — so the conviction rating is Low, deliberately.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.

Synthos fair value = the base case, ~$60 (+4%), with the full $38–$82 span as the honest range. Our base lands essentially on the Street's $60.33 price-target consensus — not because we anchored to it, but because after a ~4× run the price already sits at fair value on FY28 earnings power. DCF/multiple assumptions labeled: base applies ~17× to FY28E EPS (~$3.55 ≈ $60), consistent with a de-risked rare-disease grower still scaling toward durable profitability; we do not rely on the FMP forward EBITDA/EBIT estimate fields, which are internally inconsistent (they show deeply negative EBITDA against positive net income and SG&A estimates that exceed revenue — clearly corrupted, so we anchor on the revenue and EPS estimate lines only). The wide bull/bear spread (a 2.2× ratio) is the honest signal for a single-catalyst small-cap. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). TVTX is an earnings-inflection exponential — a company crossing from losses into profitability as a launch scales:

• Forward growth: revenue CAGR FY26E→FY30E ~26% ($698M → $1.77B); EPS goes from ~$0.20 (FY26E) → ~$2.43 (FY27E) → ~$3.55 (FY28E) → ~$4.23 (FY29E) → ~$4.80 (FY30E) — the classic profitability inflection as fixed commercial/R&D costs get spread over a fast-growing top line.
• Acceleration (the 2nd derivative): the revenue growth rate decelerates as the base grows (+110% FY25 actual → ~+42% FY26E → ~+39% FY27E → ~+22% FY28E), which is normal for a scaling launch — the earnings acceleration is the real story here, not top-line 2nd-derivative. That's why this scores 7, not 8: it's an inflection, not an accelerating-into-a-huge-TAM monster.
• Room to run: at $5.35B the company is small versus a >100,000-patient addressable population (management's figure) across IgAN + FSGS, plus Japan and HCU optionality — law-of-large-numbers is not the binding constraint; execution and competition are.
• Reinvestment / cash reality: capex is light in absolute terms but FY25 capex (−$58M) still exceeded operating CF (+$38M), leaving FCF negative (−$20.4M). This is not yet a self-funding compounding machine — the exponential is credible but cash-flow-dependent until profitability is firmly established.

Exponential Potential: High (7/10). A genuine earnings inflection with real room, tempered by thin out-year analyst coverage and a business that isn't self-funding yet.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 $490.7M, +110.4% (FY24 $233.2M, itself +60.5% on FY23 $145.2M). The multi-year arc is telling: revenue actually fell from $198M (FY20) → $110M (FY22) as legacy products were pruned, then re-accelerated on the FILSPARI launch — FY25 is the breakout year.
• Quarterly trajectory (note the lumpiness): Q1'25 $81.7M → Q2'25 $114.4M → Q3'25 $164.9M → Q4'25 $129.7M → Q1'26 $127.2M. The Q3'25 spike (and its positive net income of +$25.7M) reflects license/milestone timing, not a clean run-rate — underwrite the trend, not any single print.
• Margins: gross ~94% TTM (a pharma royalty/product profile — COGS is tiny), but operating margin −10.6% TTM and net margin −4.0% TTM. FY25 operating income was −$62.8M and EBITDA a thin +$22.2M; the FY25 net loss of −$25.5M was cushioned by +$24.7M from discontinued operations — a non-recurring item, so the continuing-operations loss (−$50.3M) is the cleaner read.
• Earnings quality — read carefully. Income-quality TTM is −0.87 (accounting income and cash income diverge and both are near/below zero), ~9% of revenue is stock-based comp ($44.9M FY25), and the license line makes quarters jumpy. This is a pre-profitability P&L; don't anchor on any single EPS figure.
• Cash flow: operating CF turned positive +$37.8M in FY25 (a real improvement from −$237M in FY24), but capex of −$58.2M left FCF −$20.4M. Still burning, just far less than before.
• Balance sheet: cash $93.0M + short-term investments $229.8M = ~$322.8M liquidity; total debt $328.7M (mostly $311.7M long-term), net debt $235.7M. Current ratio 3.1×, quick ratio 3.1×. Equity is thin at $114.8M (hence P/B 53×) against −$1.47B accumulated deficit — typical of a biotech that funded years of losses with stock. Runway is adequate but not fortress-like given the ongoing burn; a capital raise is a live risk if the launch disappoints.

6. Valuation — priced in or room?

There is no honest way to call TVTX cheap on trailing numbers, and no meaningful trailing P/E (the company lost money): EV/Sales 10.4×, P/S 10.0×, P/B 53.5×, EV/EBITDA 145× (on barely-positive EBITDA). FMP's letter rating is D+ (overall score 1/5 — every component, from DCF to ROE to P/E to P/B, scores 1/5), which mechanically reflects the losses and rich multiples rather than the growth. The bull case rests entirely on the forward line: ~24× FY27E EPS ($2.43) → ~16× FY28E ($3.55) → ~12× FY30E ($4.80) — the multiple roughly halves in two years even at a flat price if the estimates hit. A reverse read: today's $57.48 requires the IgAN+FSGS launch to actually deliver the ~26% revenue CAGR and the earnings inflection — you are underwriting execution, not buying a discount. Street price targets (context): consensus $60.33, high $67, low $49, median $65 — a relatively tight band (1.4× high-to-low) that, unusually, sits close to the current price, i.e. the sell-side sees limited near-term upside from here even while rating it Buy. Not a value buy; a fast-grower-at-full-price where the entry price is the whole debate.

7. Technicals (from the tech block)

• Trend: strongly up. $57.48 sits far above the 50-DMA ($47.78) and 200-DMA ($35.34), 50 above 200 (golden-cross posture). MACD +3.23 (positive).
• Location: only −2.6% off the 52-week high ($59.03) — that −2.6% is also the max drawdown from peak — and +293% off the 52-week low ($14.61). This is a leadership name trading at its highs, i.e. an extended entry.
• Momentum: RSI(14) 73 — overbought (above the 70 line). This is the single clearest technical caution: buyers who chase here are buying into froth.
• Relative strength: TVTX +287% 12-mo vs SPY +21% and QQQ +31%; +88.8% 3-mo vs SPY +14.6% / QQQ +23.6%. Enormous outperformance — which confirms leadership but also means a great deal of good news is already banked.
• Read: technicals are stretched, not broken — a powerful uptrend that is overbought and at its highs. The absence of any drawdown (−2.6% from peak) plus RSI 73 argues wait for a pullback: a base near the rising 50-DMA (~$48) would be a far lower-risk entry than chasing at $57.

8. Moat & competitive position

Travere's moat is regulatory exclusivity in rare kidney disease: FILSPARI is described (by management) as the first and only FDA-approved medicine in FSGS, and it holds an established position in IgAN. First/only status plus orphan-style disease focus, specialist prescriber relationships, and the switching inertia of a chronic therapy give real, if narrow, defensibility. But the moat has clear limits: (1) single-product concentration — the entire equity story is one molecule; (2) IgAN in particular has become a competitive battleground (multiple novel mechanisms — endothelin antagonists, complement inhibitors, APRIL/BAFF agents — are chasing the same nephrology prescribers), so "foundational position" must be defended, not assumed; (3) the ~94% gross margin does not translate into returns on capital yet (ROIC −13%), so the moat isn't monetized into profit.

Peer set (FMP-supplied, market cap): a cohort of clinical/commercial rare-disease and specialty biotechs — Apogee $8.2B, Centessa $6.3B, CG Oncology $6.1B, Celcuity $5.3B, Legend Biotech $5.2B, Xenon $4.8B, Ultragenyx $3.3B, Disc Medicine $2.9B, Tarsus $2.9B, Ascentage $0.45B. TVTX (~$5.3B) sits mid-pack on size but, unlike several pre-revenue names here, has a real, fast-growing commercial franchise — a genuine differentiator. Data caveat: the most direct IgAN/FSGS competitors are not cleanly represented in this list; judge FILSPARI against the nephrology launch cohort, not this heterogeneous set.

9. Management, capital allocation & guidance

• Capital allocation: no dividend, no buyback (appropriate for a cash-burning grower). FY25 financing included +$37.5M of net stock issuance and −$68.9M of net debt repayment — i.e. the company is still tapping equity at the margin while paying down debt, exactly the profile where dilution risk should be front-of-mind (§11).
• Insider activity (recent Form 4s): on 2026-06-12, two directors exercised options and sold: Timothy Coughlin (10,000 shares at ~$50.07) and Roy D. Baynes (4,500 shares at $50) — routine option-exercise-and-sell, but worth flagging as sales into the run-up (executed near $50, below today's $57). Chief Medical Officer Jula Inrig filed a small gift of 468 shares (2026-06-22), and a director received a routine RSU award (2026-05-19). No mass discretionary exit; net read is mildly negative (directors monetizing options into strength, nobody buying).
• Management guidance (half-weighted — TVTX_mgmt, skill 0.5): the six claims in §2 are the company's own launch narrative from the Q1 FY26 release. Ingested from the earnings release; full analyst Q&A is not on our FMP plan.

10. Catalysts & what to watch

• Next earnings: 2026-08-05 (Q2 FY26; Street EPS −$0.08, revenue ~$160.7M). The key line: FILSPARI net product revenue and the FSGS launch trajectory (are new FSGS scripts building, and is IgAN still growing?).
• FSGS launch metrics: prescriber breadth, reimbursement/access, and net revenue contribution — the single biggest swing factor for the whole thesis.
• SPARX study: enrollment completion (management targeted Q2 2026) in post-transplant recurrent IgAN/FSGS — a label-expansion optionality read.
• Chugai / Japan: a sparsentan NDA submission in Japan in 2026 would trigger milestone/royalty flow.
• Pegtibatinase (HCU) Phase 3 HARMONY: topline anticipated 2H 2027 — a longer-dated pipeline catalyst.
• Cash/financing signals: any capital raise, convert, or royalty-monetization announcement — given FCF is still negative.

Thesis tripwires (what would change the call): two consecutive quarters of decelerating FILSPARI revenue; a weak FSGS launch read; a dilutive equity raise; or a competitive IgAN readout that threatens FILSPARI's prescriber base.

11. Key risks

• Single-product concentration (the dominant risk): the equity is essentially a bet on FILSPARI's launch. Any clinical, commercial, or competitive setback hits the whole thesis.
• Valuation / de-rating: EV/S 10.4×, P/B 53×, RSI 73, and a price at its 52-week high on a GAAP-unprofitable company mean any disappointment re-rates hard.
• Cash burn / dilution: FCF is still negative (−$20.4M FY25) with net debt $236M; a raise is a live possibility and would dilute holders.
• Lumpy, low-quality earnings: license/milestone timing makes quarters jumpy; income quality is negative; ~9% of revenue is stock-comp.
• Competition in IgAN: a crowded, fast-moving nephrology landscape threatens the "foundational position" management touts.
• Thin forward coverage: the out-year (FY29–30) EPS estimates rest on a single analyst — the exponential case is only lightly corroborated.
• Data gaps (honesty): the geographic-revenue segment is empty in this dataset, and the FMP forward EBITDA/EBIT/SG&A estimate fields are internally inconsistent and were disregarded — we relied on the revenue and EPS estimate lines only.

12. Verdict, position sizing & monitoring

Watch. Travere is a genuine rare-disease commercial inflection — FILSPARI revenue +110% in FY25, a first/only FSGS label expanding the addressable population, operating cash flow turning positive, and a credible EPS inflection ahead. That is a real, improving business and explains the 15-Buy sell-side. But the entry price is wrong for a new position: the stock has ~4×'d in a year (+287%), sits overbought (RSI 73) just −2.6% off its high, trades essentially at the Street's $60 target and our $60 base-case fair value, and belongs to a still-unprofitable, cash-burning, single-product small-cap. The upside/downside from today's price is not attractive; the upside from a pullback would be. Hence Watch, not Buy.

• Trigger to upgrade: a pullback toward the ~$48 50-DMA (or a clean FSGS launch beat with the multiple intact) would make the risk/reward compelling — that's the price at which we'd move to Buy — Tactical.
• Sizing (if entered against this note): speculative, ~0.5–1.5% of the flagship — sized so a 40–50% drawdown (well within a small-cap biotech's range) is survivable. Do not chase at $57.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-08-05 print. This verdict is logged as a tracked Synthos call as of 2026-07-06 at $57.48.
• Single biggest risk: the FILSPARI launch curve disappointing — a one-drug company at a full price with a live dilution risk.

Provenance & disclosures

• Traceability: 6 KB claims on TVTX, all TVTX management (skill 0.5), last dated 2026-05-04 — all reconciled to real claim_ids (cited inline). There is no independent expert-panel coverage; conviction is rated Low and the note is explicitly fundamentals-driven. kb_net_conviction is left null (a single voice, not a signed aggregate).
• Data as-of: fundamentals 2026-03-31 (Q1 FY26) · estimates & prices 2026-07-06 · management claims through 2026-05-04. Forward figures are analyst consensus (FMP), labeled as estimates; out-year EPS rests on a single analyst.
• Earnings-quality caveat: FY25 GAAP net loss is cushioned by a +$24.7M discontinued-operations item; the continuing-ops loss (−$50.3M) is the cleaner read. Quarterly revenue is license/milestone-lumpy.
• Data-gap caveat: the geographic-revenue segment is empty in this dataset (no regional breakout inferred), and the FMP forward EBITDA/EBIT/SG&A estimate fields are internally inconsistent and were disregarded in favor of the revenue and EPS estimate lines.
• Management caveat: TVTX_mgmt guidance is management's own book, half-weighted by design.
• Peer caveat: the FMP-supplied peer list is a heterogeneous rare-disease/biotech cohort; the most direct IgAN/FSGS competitors are not cleanly represented — judge FILSPARI against the nephrology launch cohort.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-06. Prior versions available via the deep-dive version dropdown ("based on the info at the time").